Getting there. November can be a strong month. EOM

Ringing the bell is very exciting. If they couple it with news it will be very interesting

I almost want to jump back in to form the old band again - ha!

Steady T! Still hanging around huh? Good memories...EOM

Big TTT! I hope you're doing great man! EOM

One helluva day today. Let's hope it continues tomorrow. EOM

Yes, the set up is amazing. IMO

Surprised the board is so quiet - this stock was .50 not too long ago. The Fireside chat yesterday was extremely impressive and informative.

Hey Team!
In Navb at .60. Looking good and chart looking strong. Good luck to all!

Analysis: Positioning to Benefit within Foamix Pharmaceuticals, Era Group, Orion Group, Intermolecular, Navidea Biopharmaceuticals, and Evelo Biosciences -- Research Highlights Growth, Revenue, and Consolidated Results

8:55 am ET April 17, 2019 (Globe Newswire) Print


In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), Era Group, Inc. (NYSE:ERA), Orion Group Holdings, Inc. (NYSE:ORN), Intermolecular, Inc. (NASDAQ:IMI), Navidea Biopharmaceuticals, Inc. (NYSE:NAVB), and Evelo Biosciences, Inc. (NASDAQ:EVLO), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

FOMX DOWNLOAD: http://Capital-Review.com/register/?so=FOMX

ERA DOWNLOAD: http://Capital-Review.com/register/?so=ERA

ORN DOWNLOAD: http://Capital-Review.com/register/?so=ORN

IMI DOWNLOAD: http://Capital-Review.com/register/?so=IMI

NAVB DOWNLOAD: http://Capital-Review.com/register/?so=NAVB

EVLO DOWNLOAD: http://Capital-Review.com/register/?so=EVLO

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Capital Review, available for free download at the links above, examine Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), Era Group, Inc. (NYSE:ERA), Orion Group Holdings, Inc. (NYSE:ORN), Intermolecular, Inc. (NASDAQ:IMI), Navidea Biopharmaceuticals, Inc. (NYSE:NAVB), and Evelo Biosciences, Inc. (NASDAQ:EVLO) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

FOAMIX PHARMACEUTICALS LTD. (FOMX) REPORT OVERVIEW

Foamix Pharmaceuticals' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Foamix Pharmaceuticals reported revenue of $0.86MM vs $1.04MM (down 17.55%) and analysts estimated basic earnings per share -$0.17 vs -$0.46. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Foamix Pharmaceuticals reported revenue of $3.60MM vs $3.67MM (down 2.02%) and analysts estimated basic earnings per share -$1.70 vs -$1.76. Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.69. The estimated EPS forecast for the next fiscal year is -$1.32 and is expected to report on February 27th, 2020.

To read the full Foamix Pharmaceuticals Ltd. (FOMX) report, download it here: http://Capital-Review.com/register/?so=FOMX

-----------------------------------------

ERA GROUP, INC. (ERA) REPORT OVERVIEW

Era Group's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Era Group reported revenue of $52.02MM vs $57.53MM (down 9.59%) and analysts estimated basic earnings per share -$0.25 vs $2.95. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Era Group reported revenue of $221.68MM vs $231.32MM (down 4.17%) and analysts estimated basic earnings per share $0.64 vs -$1.36. Analysts expect earnings to be released on May 7th, 2019. The report will be for the fiscal period ending March 31st, 2019.

To read the full Era Group, Inc. (ERA) report, download it here: http://Capital-Review.com/register/?so=ERA

-----------------------------------------

ORION GROUP HOLDINGS, INC. (ORN) REPORT OVERVIEW

Orion Group's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Orion Group reported revenue of $99.21MM vs $162.21MM (down 38.84%) and analysts estimated basic earnings per share -$3.32 vs $0.34. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Orion Group reported revenue of $520.89MM vs $578.55MM (down 9.97%) and analysts estimated basic earnings per share -$3.31 vs $0.01. Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.01. The estimated EPS forecast for the next fiscal year is $0.14 and is expected to report on March 24th, 2020.

To read the full Orion Group Holdings, Inc. (ORN) report, download it here: http://Capital-Review.com/register/?so=ORN

-----------------------------------------

INTERMOLECULAR, INC. (IMI) REPORT OVERVIEW

Intermolecular's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Intermolecular reported revenue of $6.32MM vs $10.55MM (down 40.07%) and basic earnings per share -$0.06 vs $0.01. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Intermolecular reported revenue of $33.66MM vs $37.20MM (down 9.52%) and analysts estimated basic earnings per share -$0.07 vs -$0.21. Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019.

To read the full Intermolecular, Inc. (IMI) report, download it here: http://Capital-Review.com/register/?so=IMI

-----------------------------------------

NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) REPORT OVERVIEW

Navidea Biopharmaceuticals' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Navidea Biopharmaceuticals reported revenue of $0.12MM vs $0.40MM (down 69.81%) and analysts estimated basic earnings per share -$0.01 vs -$0.02. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Navidea Biopharmaceuticals reported revenue of $1.17MM vs $1.81MM (down 35.41%) and analysts estimated basic earnings per share -$0.09 vs $0.47. Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019.

To read the full Navidea Biopharmaceuticals, Inc. (NAVB) report, download it here: http://Capital-Review.com/register/?so=NAVB

-----------------------------------------

Still breaking out! Eom

Conference Call

Navidea Biopharmaceuticals Schedules Conference Call to Discuss Future Outlook and Outcomes of Court Trial
Download as PDF April 03, 2018
Conference call to take place Thursday April 5, 2018 at 8:30am E.T.

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals (NYSE MKT: NAVB) (“Navidea” or “the Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call on April 5, 2018 at 8:30am E.T. to discuss its future outlook following the outcome of the court case in Texas with Capital Royalty Group (CRG).

Michael Goldberg, President and Chief Executive Officer, and Jed Latkin, Chief Financial and Operating Officer of Navidea, will host the call and provide an update on recent developments and the strategy going forward.

To participate in the call, please dial +1 929-477-0448 (toll-free) in the U.S. and Canada. The conference ID number is 6756561.

Event: Navidea Future Outlook and Trial Outcome Call
Date: Thursday, April 5, 2018
Time: 8:30am E.T.
U.S. & Canada Dial-in: +1 929-477-0448 (toll free)
Conference ID: 6756561

A live audio webcast of the conference call will also be available on the investor relations page of Navidea’s corporate website at www.navidea.com. In addition, the recorded conference call can be replayed and will be available for 90 days following the call on Navidea’s website.

Spotlight partner. http://nash-summit.com/partner/partners

Navidea to Host Moderated Q&A Webcast with Management
Download as PDF
February 01, 2018
Webcast is scheduled with CFO Jed Latkin for Tuesday, February 13th at 5:00 p.m. ET
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today that it will hold an online Question & Answer (Q&A) Session with Jed Latkin, Chief Financial and Operating Officer, and Fred Cope, Ph.D., Chief Scientific Officer of Navidea, on Tuesday February 13, 2018 at 5:00 p.m. Eastern Time. Investors are invited to submit questions they would like to hear answered to ir@navidea.com or tpatel@edisongroup.com by Friday, February 9, 2018.
From time to time, between quarterly conference calls, the management will host Q&A webcasts so investors and potential investors can learn more about the Company, its strategy, and its products.
Event:

Navidea Q&A Session – February 2018
Date:

Tuesday, February 13th, 2018
Time:

5:00 p.m. Eastern
US/Canada Toll-Free:

800-239-9838
Conference ID:

9621939
Webcast:

http://www.audio-webcast.com/cgi-bin/visitors.ssp?fn=visitor&id=5287

Nice day today with trading/volume. IMO

Getting interest. Navidea will have a positive 2018. IMO

Hi Beambe,
I'll be taking a position next week. 2018 May have good progress in clearing out court issues etc.
Thanks and good luck!

The force is with you LKJ

Hope you're doing great Tadaaa!!eom

Appreciate it Freebies! Eom

Sure didn't passin - I took a glance late and went "what the heck?"

Thank you for everything my friend! Make sure to PM me!! eom

Hope you're doing great T! eom

Thank you for your diligence Morg...

You see it going to .003 Jaconow?

You too T! Getting warm over here....hmmmm

Yes sir!

Yeah T, but this volume is bananas...

Hahaha. Good one T!

But on FaceBook? That definitely wont amount to much.
IMO

Then we need a serious amount of air! lol

hahaha Steady! This stock has become a complete parody of itself.
I guess Sym has turned into Casper?

Yeah, lulls like this are NOT good. IMO

Sym, any words for your loyal investor's??? eom

Done.eom

All up to Sym. There's so many easy options for him to get the PPS up. I'm surprised he's not utilizing his options. JS, give me a call if you need a tutorial. Lol

Let's make money! Sym give us the word! EOM

Got it. Thanks Doo.eom

Wait a minute here. Your whole platform has been to protect "new investors." Yet you flipped a few times at a good profit? Now you hold freebies? hahahaha!! You're also going off of speculation?? You've been HAMMERING people who have this same objective for months!!! Lou, c'mon man...

Agreed. Big jump for so little shares...eom